Hydron Tech. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hydron Tech.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew G. who wrote (18)	4/24/1997 2:16:00 AM
From: Dave K	of 72

Andrew and Edward: Interesting dialog. Even though the QVC minimums may not be met, why won't they simply amend the previous agreement with QVC as they did last year?. Seems like QVC and Hydron have a longstanding relationship. QVC now has a "reasonable" vested interest to see them succeed: As part of the amended license agreement last year QVC had options to purchase 500,000 shares at $2.50 per share. Hydron also granted QVC an option to purchase an additional 500,000 shares at $2.75 per share. A $1.75 stock price must hurt them. Hydron's products appeal to those using them. Only thing lacking is broader brand name recognition as you said. As far as medical application, everyone has a polymer "something" these days. Their increased sales don't seem to justify the current price. I'm wondering if DTR's president has been unloading his options and responsible for the current weakness. If so, the smart money may return once he gets through. Any thoughts ? Dave.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next